PXL/HO/Cir-016/2019-20 Date: 22.05.2019
Subject: UNIQUE OPPORTUNITY: Training programme on "Regulatory Procedures for APIs and Formulations in China "by National Medical Products Administration (NMPA) on 21st June 2019 at Shanghai, China
Member companies are aware, China is an important market for Indian pharma and recently there were many changes in the regulatory systems of China, primarily transforming from CFDA to NMPA. Pharmexcil has taken up major issues with NMPA through our Mission in China and Commerce Ministry and a training programme have been sought with NMPA.
Pursuant to the efforts of Embassy of India, Commerce Ministry and Pharmexcil, the regulatory authority of China (NMPA) has agreed to provide the Training on "Regulatory Procedures for API and Formulations & recent changes" for the benefit of Indian Pharmaceutical companies. It will be a full day programme and there is no Registration Fee for member companies.
The training programme is scheduled for 21st June 2019, a day after CPhI China, as the majority of pharmaceuticals companies will be present in Shanghai, China. Senior Officials from NMPA, CDSCO, Embassy of India and Commerce Ministry will be attending the programme.
Member companies are advised to avail this unique opportunity by registering their participation at email@example.com. Pharmexcil will provide required assistance to the confirmed delegates in arranging Visa invitation.
We look forward to your active participation.